University of Pittsburgh Clinical and Translational Science Institute

摘要 由新型SARS-COV-2病毒引发的大流行继续对 世界各地社区的身体、社会和经济健康。为评估流行性出血热的血清流行率 美国对SARS-COV-2的免疫，这是临床和翻译的科学伙伴关系 学术医学中心(阿拉巴马大学和匹兹堡大学)的科学奖(CTSA) 和国家过敏和传染病研究所(NIAID)传染病实验室 鉴定、登记和获取了11,300名未被诊断为霍乱的成年人的血液样本 代表美国几乎每个县和所有主要种族和民族的新冠肺炎。我们现在就会 寻求这些参与者的同意，以便在6个月和12个月后提供随访数据和血样 登记(目标1)和确定与健康结果有关的免疫属性(目标2)，包括 对于那些在人口中代表性不足的人和整个生命过程。这一合作伙伴关系 内部NIAID计划和外部资助的CTSA中心将有效地调查、获取血液样本 根据并确定SARS-CoV-2抗体在一大群不同类型人群中的流行变化 无已知临床新冠肺炎病的成人。从这项血清效价研究中获得的知识将 从人群层面提高对SARS-CoV-2体液免疫的认识 疫苗接种战略--既针对新冠肺炎大流行，也针对未来涉及新病原体的流行病。

ABSTRACT The pandemic prompted by the novel SARS-COV-2 virus continues to have a devastating effect on the physical, social, and economic health of communities throughout the world. To evaluate the sero-prevalence of immunity against SARS-COV-2 in the United States, this scientific partnership of Clinical and Translational Science Awardees (CTSAs) at academic medical centers (University of Alabama and University of Pittsburgh) and the National Institute of Allergy and Infectious Diseases (NIAID) Laboratory of Infectious Disease identified, enrolled, and obtained blood samples from 11,300 adults who have not been diagnosed with COVID-19 representing almost every county in the US and all major racial and ethnic groups. We will now seek consent from these participants to provide follow-up data and blood samples and 6 and 12 months after enrollment (Aim 1) and determine the immune attributes associated with health outcomes (Aim 2), including for those in underrepresented populations and across the life course. This collaborative partnership of the intramural NIAID program and extramurally funded CTSA Hubs will efficiently survey, obtain blood samples from, and determine changes in the prevalence of SARS-CoV-2 antibodies in a large, heterogeneous cohort of adults without known clinical COVID-19 disease. Knowledge gained from this seroprevalence study will advance our understanding of SARS-CoV-2 humoral immunity at the population level and inform population strategies for vaccination – both for the COVID-19 pandemic and future epidemics involving novel pathogens.